# A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients

Source: https://onco.cc/trials/nct06469879/  
OnCo record `nct06469879` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of benmelstobart and anlotinib in lung cancer, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., not yet recruiting.

## Summary

A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer Patients is a phase 3, randomised interventional study registered as NCT06469879 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with a registry enrolment figure of 358 participants, started 2024-09 and due to reach its primary completion in 2026-09. Interventions recorded: TQB2450+Anlotinib; TQB2450 placebo + Anlotinib placebo. Conditions listed: Small Cell Lung Cancer Limited Stage. Primary outcome: Progression-free survival (PFS) evaluated by the Independent Review Committee (IRC). Lung eligibility wording from the registry: "* Pathologically confirmed patients with limited stage small cell lung cancer (according to the Veterans Administration Lung Study Group (VALG) stage);". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06469879
- Phase: 3
- Setting: A Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of TQB2450 Combined With Anlotinib as Maintenance Therapy in Patients With Limited-stage Small Cell Lung Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 358

## Sources

- ClinicalTrials.gov NCT06469879: https://clinicaltrials.gov/study/NCT06469879

## Connected records

- cancers: [Limited-stage small-cell lung cancer](https://onco.cc/cancers/limited-stage-sclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Benmelstobart](https://onco.cc/drugs/benmelstobart/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06469879.json